Stereotaxis, Inc. (STXS)

The past six months have seen several significant regulatory and commercial milestones for Stereotaxis, Inc., which have generally coincided with modest positive stock price reactions. In August 2025, Stereotaxis reported Q2 earnings with revenue reaching $8.8 million, up 95% year-over-year. In September 2025, the stock experienced double-digit gains, reaching as high as over 40% in the past six months. In October 2025, the company announced European CE Mark receipt and FDA submission for its Synchrony digital cath lab technology. In November 2025, Stereotaxis reported Q3 financial results with total revenue of $7.5 million, and the GenesisX robotic system received U.S. FDA regulatory clearance. MAGiC Sweep generated over $300,000 in revenue within its first two months of launch. In January 2026, Stereotaxis' MAGiC received FDA approval. Despite these positive developments, the stock price declined by 1.69% from January 30, 2025, to January 29, 2026. The company has also been operating with a net loss, reporting $6.5 million in Q3 2025, and negative free cash flow.

Stereotaxis, Inc. experiences demand seasonality, particularly affecting its recurring revenue from procedures. The company's Q3 2025 financial results indicated "summer seasonality in procedure volumes" which counteracted positive momentum from new product launches. This suggests that procedure volumes, and consequently the demand for disposable catheters and services, may be lower during summer months.

Stereotaxis, Inc. is a global leader in surgical robotics, specializing in minimally invasive endovascular intervention for treating complex cardiac arrhythmias. The company operates within the medical technology sector, focusing on robotic systems, instruments, and information solutions for the interventional laboratory. Its major products include Genesis RMN System and GenesisX RMN, MAGiC Ablation Catheter, MAGiC Sweep Catheter, Odyssey, Synchrony System & SynX, Niobe System, Stereotaxis imaging model S x-ray system, and disposables and other accessories. The company's business model is transitioning to a "razor-and-blades" strategy, with robotic systems as the "razor" and disposable catheters and service contracts as the "blades."

Stereotaxis, Inc. designs, manufactures, and markets its products in the United States and internationally. Its technology has been used in over 150,000 patients across the United States, Europe, Asia, and elsewhere. The company has a strategic relationship in China, which is becoming a new "geographic pillar" for its commercial efforts. Its global headquarters are located in St. Louis, Missouri, USA.

In the past year, Stereotaxis has maintained its reputation as a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention. Key events that have positively impacted its reputation include regulatory approvals, product launches and commercial progress, strategic collaborations, and clinical efficacy. The company received significant regulatory clearances, including FDA approval for its GenesisX robotic system and for the MAGiC ablation catheter. The early commercial sales and positive momentum of new proprietary robotically navigated devices like MAGiC and MAGiC Sweep have been highlighted. The company announced a collaboration with CardioFocus to advance the first robotically-navigated pulsed-field ablation electrophysiology catheter solution. The MAGiC catheter has demonstrated a strong 94% acute efficacy rate in clinical trials.

Stereotaxis, Inc. is a publicly traded medical technology company with a mix of institutional, insider, and public shareholders. As of September 30, 2025, institutional investors hold approximately 45.35% of the company's shares, while insiders hold 17.77%. Major institutional owners include DAFNA Capital Management LLC, Lagoda Investment Management, L.P., BlackRock, Inc., Vanguard Group Inc, Arbiter Partners Capital Management LLC, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Essex Investment Management Co Llc, Geode Capital Management, Llc, iShares Russell 2000 ETF (IWM), and Archon Capital Management LLC.